Research & development
00:00 [Music: Forward moving, positive & quirky electronica underscore with glistening, rhythmical synths & driving bassline.]
00:01-00:05 [A female scientist in a lab, looking at an automated pipetting robot. Cut to the same woman standing in the middle of the lab, looking directly at the camera. Red words “WE GO BOLD” appear on the screen.]
Narrator 1: We go bold every day.
00:05-00:08 [Medium close-up of male Narrator two delivering line to the camera.]
Narrator 2: That's how real, game-changing innovation happens.
00:08-00:10 [A person grabs a white Lilly lab coat hanging on the wall. Cut to a closeup of a person putting on the white Lilly lab coat.]
00:10-00:13 [The camera pans around a glass wall with the Lilly logo. Cut to a male scientist in a lab, dropping liquid into a test tube.]
Narrator 2: By looking at what others deem impossible or too risky
00:13-00:15
[Medium close-up of male Narrator two delivering the line to the camera.] and embracing it as a challenge,
00:15-00:16
[Close-up of a male scientist holding an orange test tube with a disappointed look on his face.] as an opportunity.
00:16-00:17
[Close-up of a female scientist smiling and nodding at the scientist from the previous clip. Cut to a medium shot of both of them looking at the test tube in the lab.]
Narrator 3: Let's try that again.
00:18-00:21 [Narrator four stands at a desk in a library and delivers her lines to the camera. Red words “BOLD DECISIONS” appear on the screen behind the subject.]
Narrator 4: An opportunity to make bold decisions.
00:21-00:27 [Two scientists working in a laboratory, discussing or analyzing data on a whiteboard filled with chemical formulas and notes. Cut to close-ups of both scientists.]
Narrator 5: Tackling some of society's most difficult, complex diseases, like neurodegeneration, obesity,
00:27-00:32
[Close-up of a scientist looking through a microscope; the scientist is wearing protective goggles and a mask. Cut to a close-up of the microscope dial and a hand moving the dial counterclockwise. Microscope view of red blood cells. Cut to a close-up of the same scientist looking through the microscope.]
cardiovascular disease, diabetes, cancer, and immunological disorders.
00:32-00:34
[Scientist from the previous scene looking directly at the camera. Red words “BOLD SOLUTIONS” appear on the screen.]
Investing in bold solutions,
00:34-00:37
[Syringes pass through inspection quickly on the production line. Cut to a female having a virtual call on her laptop.]
accelerated speeds, and a heightened purpose
00:37-00:40
[A young boy hugs a female in a wheelchair.] to help people get better.
00:40-00:45
[A close-up shot of a female scientist in the lab, looking through a microscope. Cut to a shot of her hands, holding tweezers, and then cut to a wide shot with a computer screen that displays the microscope view. Red words “BOLDLY PIONEER” appear on the screen.]
Narrator 1: An opportunity to boldly pioneer new technologies
00:45-00:48
[A female scientist walks away from a computer. Cut to a pipetting robot arm gliding across plastic trays. Cut to a close-up of the machine, lowering droppers into test tubes.] that will redefine the boundaries of possibility,
00:48-00:50
[Female Narrator one delivers lines to the camera.] from discovery to delivery,
00:50-00:55
[Quick flashes of images: liquid going into a test tube, liquid dispersing onto a test slide, close- up of microscope parts, and quick cuts of multiple cells from the microscope view.] directly shaping the future of science itself.
00:55-00:56
[Female Narrator six delivers lines to the camera.]
Narrator 6: To be relentless
00:56-00:58 [Close-up of a medical book on a table; a person’s hands touch the book. Cut to a woman looking off in the distance, processing the information she just read.] in the pursuit of unexplored pathways,
00:58-01:01
[Wide shot of the previous woman, typing on a computer. Red words “BOLD CURIOSITY’ appear on the screen.]
fueled by a bold curiosity and the commitment to make life better
1:01-1:04
[Narrator six delivers the line to the camera. Cut to hands starting to open a pill organizer.] for people around the world.
01:05-01:08 [Continuation of the previous shot. Cut to a woman being slowly moved into an MRI machine.]
Narrator 4: This commitment goes beyond the pipeline of molecules we're creating
01:08-01:11
[A doctor administers a shot into a patient’s arm.] and extends to the entirety of the patient experience.
01:11-01:14
[Over-the-shoulder shot of a scientist examining brain scans on a display in front of them. Cut to two hands intertwining. Cut to a close-up of an eye. Cut to the sun peeking out behind an apartment building.]
Narrator 5: To remove barriers to access our medicines and live healthier lives.
01:17-01:18 [Narrator two delivers the line to camera.]
Narrator 2: Embrace challenges.
01:18-01:19 [Narrator six delivers the line to camera.]
Narrator 6: Take risks.
01:19-01:20 [Narrator four delivers the line to camera.]
Narrator 4: Be persistent.
01:20-01:22 [Narrator one delivers the line to camera.]
Narrator 1: Exceed expectations.
01:22-01:26
[A scientist looks down; his head is framed between beakers full of orange liquid. Cut to a wide shot of him examining the beakers in a lab; a second scientist is on a computer behind him.] Hmm, sounds bold. At Lilly,
01:26-01:35
[Narrator one sits at a desk in a library and speaks to the camera. Cut to white text over red background: “BOLD SCIENCE HAPPENS HERE.” Cut to Lilly logo over red with text under it: “A MEDICINE COMPANY.”]
bold science happens here.
name of science
Called to discover,
driven to deliver
~50
~6 years
23
Alzheimer's disease
Cancer
Cardiovascular disease
Diabetes
Immunology
Obesity
Pain
and non-opioid medicines to enable
a better approach to comprehensive
pain management.
1923
available insulin product
1940s
method to mass-produce Penicillin-G,
the world’s first widely available
antibiotic
1955
and distribute the polio vaccine globally
1963
a vinca alkaloid, in 1963 for leukemia
treatment
1964
cephalosporin, was approved in 1964
in the U.S
1986
2020
antibody (mAB) therapy that received FDA approval to treat
coronavirus (SARS-CoV-2)
2022
agonist approved for type 2 diabetes
(2022) and obesity (2023) in the U.S
2024
2024
targeting therapy with dosing
instructions that allow for a limited-
duration treatment regimen approved for
the treatment of early Alzheimer's
disease in the U.S
00:00-00:10 (The video begins with Laura Michael sitting in a chair by a window with a view of the outside.) Over 10 years ago, we conceived of a project that was really technically challenging and a lot of people found it very hard to believe we could create a molecule.
00:11-00:15 And through many learning cycles, we've increased the potency and the specificity of this molecule.
00:16-00:19 But we had one side effect that we were always worried about.
00:20-00:21 And in fact, it happened.
00:22-00:39 It emerged in preclinical models, and the team felt so discouraged that we wouldn't be able to carry the molecule forward until we sat back, studied the reason why it was happening, and we learned that it probably wouldn't happen in people and we could explain it from a molecular standpoint.
00:40-00:47 We were given the chance to put it into people and it was potent, efficacious, and it didn't have the side effect because we designed it.
00:48-00:58 And that was so elating to know that the team worked so hard and thought so critically about that molecule and how it should work.
00:59-01:04 And then to see the results in phase one clinical trial was so inspiring.
01:05-01:10 So you have to continually challenge yourself to think something through, maybe in a different way.
01:11-01:15 The camera fades off Laura, and the white Lilly logo appears over a red background.
00:00-00:01 (The video begins with Lisa Broad sitting in a chair by a window with a view of the outside.)
We're doing a lot of work in chronic pain.
00:02-00:09
So we were working on a molecule, which once again, we've taken all the way through to clinical proof of concept in chronic pain conditions.
00:10-00:24
I think one of the very cool things about this particular project, we were able to put it into the Chronic Pain Master protocol, which is a really cool, innovative approach that Lily's done that no one else in pain has done.
00:25-00:31
If you take a molecule forward, you often don't know what pain state it's going to work in, and you have to guess.
00:32-00:36
So we've taken that guesswork out of the equation with the Chronic Pain Master Protocol.
00:37-00:45
The drugs all go into three big representative chronic pain States and we were able to put our molecule into that Chronic Pain Master protocol.
00:46-00:51
And Lily has done that for three now 4 molecules in the last couple of years and done 9 proofs of concept studies.
00:52-00:54
That's really bold, that's really innovative.
00:55-00:58
And that enabled us to to get to data for that method mechanism.
00:59-01:05
The second example I have is we are working on ALS, amyotrophic lateral sclerosis.
01:06-01:07
That's a newer area for Lily.
01:08-01:10
The project team I'm working on for ALS is in Phase 1.
01:12-01:15
So it's in the clinic and it's a first in class opportunity.
01:16-01:21
So, so Lily is in the lead with delivering that potential new therapy to patients.
01:22
It's very exciting.
01:23-01:28
And the innovation there comes from actually being able to perhaps put that molecule into an external master protocol.
01:29-01:31
Again, we talked about how master protocols are very efficient.
01:32-01:41
They enable you to, to get to data faster and again, that will be tremendous for us to tap into external master protocol that's already going and doing well.
01:42-01:47
You know, I've, I've been working in this business for over 25 years, 30 years.
01:48-01:50
And I'm like, I don't have that many years left, you know, to, to continue.
01:51-01:53
So for me that there's this urgency, right?
01:54-02:05
To take everything I've learnt and to have impact, have impact the patients, but also to help train the next generation of drug hunters, right, because there's still so much to do.
02:06-02:10
The camera fades off Lisa, and the white Lilly logo appears over a red background.
00:00-00:08 (The video begins with Michael Krautkramer sitting in a chair by a window with a view of the outside.)
One of the most exciting things about working at Lily is so many of the projects that we get sometimes don't look very possible and it fails more often than not.
00:09-00:11
So you kind of start, start from a position of like, like, is this impossible?
00:12-00:13
And I think those are the most fun projects to work on, right?
00:14-00:26
So one of the the projects that been most excited to be a part of was this project to figure out how do we deliver our drugs better into the brain.
00:27-00:30
And when you deliver a drug peripherally like less than 1% actually gets into the brain.
00:31-00:35
So like anything we can do to increase that to 2% is 100% improvement for Lilly.
00:36
It's a big deal to hit portfolio, Andrew.
00:37-00:41
We were able to move not one, not two, but three assets into the portfolio.
00:42-00:47
You're fortunate, maybe call it locked up the PO CS work to the science that our team predicted ended up playing out.
00:48-00:58
We know that's not always the case, but but I think that there is this this again element back to like the the trust we put in the individual team members to deliver on what they needed to deliver.
00:59-01:02
The camera fades off Michael, and the white Lilly logo appears over a red background.